Treatment options for recurrent high-grade gliomas

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Pranckeviciene A, Bunevicius A. Depression screening in patients with brain tumors: a review. CNS Oncol. 4(2), 71–78 (2015).
  CASGoogle Scholar
• 2 Apuzzo MLJ. Malignant Cerebral Glioma. American Association of Neurological Surgeons, Park Ridge, USA, 79–89 (1990).
  Google Scholar
• 3 Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683–2710 (2007).
  Medline CASGoogle Scholar
• 4 Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 110(1), 13–24 (2007).
  MedlineGoogle Scholar
• 5 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005). •• Seminal article describing the establishment of a standard treatment for glioblastoma (GB) consisting of concomitant chemoradiotherapy with temozolomide (TMZ) followed by 6–12 cycles of adjuvant TMZ.
  Medline CASGoogle Scholar
• 6 Davis FG, Freels S, Grutsch J et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J. Neurosurg. 88, 1–10 (1998).
  Medline CASGoogle Scholar
• 7 Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 88, 2887 (2000).
  Medline CASGoogle Scholar
• 8 National Comprehensive Cancer Network. NCCN guidelines: central nervous system cancers. www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  Google Scholar
• 9 Ammirati M, Galicich JH, Arbit E, Liao Y. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21, 607–614 (1987).
  Medline CASGoogle Scholar
• 10 Hervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery 75(5), 491–499 (2014). •• A large scale systematic review analyzing efficacy of re-resection for GB.
  MedlineGoogle Scholar
• 11 Barbagallo GM, Jenkinson MD, Brodbelt AR. Recurrent glioblastoma multiforme – when should we reoperate? Br. J. Neurosurg. 22(3), 452–455 (2008). • Study indicating specific factors such as age and tumor volume that contribute to increased likelihood of survival time prolongation after re-resection of GB.
  MedlineGoogle Scholar
• 12 Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol. 28(24), 3838–3843 (2010).
  MedlineGoogle Scholar
• 13 Pinsker M, Lament C. Experiences with reoperation on recurrent GBM. Zentralbl. Neurochir. 62(2), 43–47 (2001).
  Medline CASGoogle Scholar
• 14 Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma – are we there yet? Neuro Oncol. 15(1), 4–27 (2013).
  MedlineGoogle Scholar
• 15 Franceschi E, Bartolotti M, Tosoni A et al. The effect of re-operation on survival in patients with recurrent glioblastoma. Anticancer Res. 35(3), 1743–1748 (2015).
  MedlineGoogle Scholar
• 16 Mandl ES, Dirven CM, Buis DR et al. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg. Neurol. 69(5), 506–509 (2008).
  MedlineGoogle Scholar
• 17 Bloch O, Han SJ, Cha S et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J. Neurosurg. 117(6), 1032–1038 (2012).
  MedlineGoogle Scholar
• 18 Oppenlander ME, Wolf AB, Snyder LA et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. J. Neurosurg. 120(4), 846–853 (2014).
  MedlineGoogle Scholar
• 19 Miller K, Wang M, Gralow J et al. Paclitaxel plus bavacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 257(26), 2666–2676 (2007).
  Google Scholar
• 20 Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26(12), 2013–2019 (2008).
  Medline CASGoogle Scholar
• 21 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
  Medline CASGoogle Scholar
• 22 Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27(28), 4733–4740 (2009).
  Medline CASGoogle Scholar
• 23 Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27(5), 740–745 (2009).
  Medline CASGoogle Scholar
• 24 Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722–4729 (2007).
  Medline CASGoogle Scholar
• 25 Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 72(14), 1217–1222 (2009).
  Medline CASGoogle Scholar
• 26 Taal W, Oosterkamp HM, Walenkamp AM et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled Phase II trial. Lancet Oncol. 15(9), 943–953 (2014). •• The first randomized controlled Phase II trial of bevacizumab therapy in recurrent GB evaluating its efficacy versus CCNU monotherapy (lomustine) and combination therapy.
  Medline CASGoogle Scholar
• 27 Forst D, Neagu M, Eisele S. SNO 2015: new clinical research presentations. Presented at: 20th Annual Scientific Meeting of the Society for Neuro-Oncology. San Antonio, TX, USA, 19–22 November 2015.
  Google Scholar
• 28 McCarty JH. Glioblastoma resistance to anti-VEGF therapy: has the challenge been MET? Clin. Cancer Res. 19(7), 1631–1633 (2013).
  Medline CASGoogle Scholar
• 29 Keunen O, Johansson M, Odin A. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl Acad. Sci. USA 108(9), 3749–3754 (2011).
  Medline CASGoogle Scholar
• 30 Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent GBM. J. Neurooncol. 56(2), 183–188 (2002).
  MedlineGoogle Scholar
• 31 Prados MD, Lamborn K, Yung WK et al. A Phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 8(2), 189–193 (2005).
  Google Scholar
• 32 Perry JR, Rizek P, Cashman R et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113(8), 2152–2157 (2008).
  Medline CASGoogle Scholar
• 33 Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 256(5), 734–741 (2009). • Unique study suggesting TMZ rechallenge monotherapy is a promising therapeutic for management of recurrent GB.
  Medline CASGoogle Scholar
• 34 Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12(2), 259–266 (2001).
  Medline CASGoogle Scholar
• 35 Brandes AA, Ermani M, Basso et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a Phase II study. Ann. Oncol. 12(2), 255–257 (2001).
  Medline CASGoogle Scholar
• 36 Han SJ, Rolston JD, Molinari AM et al. Phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. Neuro Oncol. 16(9), 1255–1262 (2014).
  MedlineGoogle Scholar
• 37 Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22(1), 133–142 (2004).
  Medline CASGoogle Scholar
• 38 Uhm JH, Ballman KV, Wu W et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 80(2), 347–353 (2011).
  Medline CASGoogle Scholar
• 39 van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27(8), 1268–1274 (2009).
  Medline CASGoogle Scholar
• 40 Chen L, Han L, Shi Z et al. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway. Mol. Med. Rep. 5, 575–579 (2012).
  Medline CASGoogle Scholar
• 41 Wollmann G, Ozduman K, van den Pol AN. Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J. 18(1), 69–81 (2012).
  Medline CASGoogle Scholar
• 42 Ampie L, Choy W, Lamano JB et al. Heat shock protein vaccines against glioblastoma: from bench to bedsire. J. Neurooncol. 123(3), 441–448 (2015).
  Medline CASGoogle Scholar
• 43 Bloch O, Crane CA, Fuks Y et al. Heat-shock protein peptide complex-96 vaccination for recurrent GBM: a Phase II, single-arm trial. Neuro Oncol. 16(2), 274–279 (2014).
  Medline CASGoogle Scholar
• 44 Swartz AM, Li QJ, Sampson JH. Rindopepimut: a promising immunotherapeutic for the treatment of GBM. Immunotherapy 6(6), 679–690 (2014). • A randomized controlled Phase II study revealing efficacy of novel immunotherapeutic Rintega when combined with bevacizumab for GB treatment.
  CASGoogle Scholar
• 45 Schumacher T, Bunse L, Pusch S et al. A vaccine targeting mutant IDH1 induces antitumor immunity. Nature 512, 324–327 (2014).
  Medline CASGoogle Scholar
• 46 Dimitrov L, Hong CS, Yang C et al. New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int. J. Med. Sci. 12(3), 201–213 (2015).
  Medline CASGoogle Scholar
• 47 Hdeib A, Sloan AE. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax platform in the treatment of GBM. CNS Oncol. 4(2), 63–69 (2012).
  Google Scholar
• 48 Skeie BS, Enger PO, Brogger J et al. Gamma knife surgery versus reoperation for recurrent glioblastoma multiforme. World Neurosurg. 78(6), 658–669 (2012).
  MedlineGoogle Scholar
• 49 Shrieve DC, Alexander E III, Wen PY et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36, 275–284 (1995).
  Medline CASGoogle Scholar
• 50 Kunwar S, Chang S, Westphal M et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 12(8), 871–881 (2010).
  Medline CASGoogle Scholar
• 51 Chicoine MR, Won EK, Zahner MC. Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery 48(3), 607–614 (2001).
  Medline CASGoogle Scholar